{
    "nct_id": "NCT03939026",
    "official_title": "A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma",
    "inclusion_criteria": "* Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular Lymphoma.\n* Relapse or refractory disease after at least 2 lines of chemotherapy\n* At least 1 measurable lesion at time of screening.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Adequate hematological, renal, liver, pulmonary, and cardiac functions.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or history of central nervous system (CNS) lymphoma.\n* Clinically significant CNS dysfunction.\n* ASCT within last 6 weeks or allogeneic HSCT within last 3 months prior to ALLO-647.\n* Prior treatment with anti-CD19 therapy, any gene therapy, any genetically modified cell therapy or adoptive T cell therapy\n* Systemic anticancer therapy within 2 weeks prior to study entry.\n* On-going treatment with immunosuppressive agents.\n* Active acute or chronic graft versus host disease (GvHD), or GvHD requiring immunosuppressive treatment within 4 weeks of enrollment.\n* Any form of primary or acquired immunodeficiency (e.g., severe combined immunodeficiency disease).\n* Current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy.\n* Patients unwilling to participate in an extended safety monitoring period",
    "miscellaneous_criteria": ""
}